Twist Bioscience Stock Tops Analyst Targets After Guidance Raise and Amazon Partnership
NEW YORK, April 15 —
Twist Bioscience raised guidance and landed an Amazon partnership, sending shares to $56.87, above Barclays' freshly raised $55 price target.
- Barclays raised its TWST price target to $55, which the stock has already passed at $56.87
- Forward P/E sits at -30.2x on $392mn TTM revenue, meaning profitability is still a promise, not a fact
- Next earnings will be the first real test of whether raised guidance and Amazon revenues show up in actual results
What Actually Happened
Twist Bioscience, which manufactures synthetic DNA using a silicon-based platform, got the analyst upgrade cycle every growth stock dreams about. The company raised its own guidance, Barclays bumped its price target to $55, and Guggenheim reiterated its rating while flagging an Amazon partnership as a new catalyst. The stock climbed on all of it.
The Amazon tie-up is the detail worth paying attention to. Synthetic biology companies have spent years trying to convert Big Tech interest into recurring revenue. If Amazon is buying synthetic DNA at scale for data storage or another application, that's a commercial validation that matters more than any analyst note. Guggenheim clearly thinks so.
The Catch
Two things should keep investors honest here. First, insiders were selling shares into this rally. That doesn't always mean trouble. Executives sell stock for all kinds of reasons. But when a company raises guidance and its own officers lighten their positions at the same time, it's at least worth noting the pattern.
Second, the math is awkward. Barclays just raised its target to $55, and the stock is already at $56.87. When a stock outruns its own upgrades on the day they're published, the market is pricing in more optimism than Wall Street is willing to underwrite. The negative forward P/E confirms Twist is still burning cash. Revenue of $392mn on a trailing basis is real and growing, but this valuation requires the guidance raise to be a floor, not a ceiling.
Bottom Line
This is a better story than it was a month ago. A guidance raise plus a credible tech partnership is the kind of one-two punch that moves a mid-cap biotech out of the "speculative" bucket and into the "show me" bucket. But the stock trading above its freshest price target tells you the easy move already happened. The number to watch is next quarter's revenue. If it tracks ahead of the new guidance, the re-rating continues. If it merely meets the raised bar, this price has nowhere to go.
There's no existing Basis Report coverage for Twist Bioscience yet. Generate a full TWST report here to dig into the financials.
Basis Report does not hold positions in securities discussed. This is not investment advice.